Biomarkers Predicting Antidepressant Treatment Response: How Can We Advance the Field?
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Major depression, affecting an estimated 350 million people worldwide, poses a serious social and economic threat to modern societies. There are currently two major problems calling for innovative research approaches, namely, the absence of biomarkers predicting antidepressant response and the lack of conceptually novel antidepressant compounds. Both, biomarker predicting a priori whether an individual patient will respond to the treatment of choice as well as an early distinction of responders and nonresponders during antidepressant therapy can have a significant impact on improving this situation. Biosignatures predicting antidepressant response a priori or early in treatment would enable an evidence-based decision making on available treatment options. However, research to date does not identify any biologic or genetic predictors of sufficient clinical utility to inform the selection of specific antidepressant compound for an individual patient. In this review, we propose an optimized translational research strategy to overcome some of the major limitations in biomarker discovery. We are confident that early transfer and integration of data between both species, ideally leading to mutual supportive evidence from both preclinical and clinical studies, are most suitable to address some of the obstacles of current depression research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
(2013) · The Lancet · doi:10.1016/s0140-6736(12)62129-1 · Cited by 3,010 · cited 1×
“With respect to disease vulnerability genes, a very recent approach from the Psychiatric Genomics Consortium moved forward in that they combined the analyses of genome-wide single nucleotide polymorphism (SNP) data for more than 33000 cases and more than 27000 controls distributed among the five major psychiatric diso…”
BackgroundBrain corticosteroid receptor balance in health and disease
de Kloet, E. R., Vreugdenhil, E., Oitzl, M. S., & Joëls, M. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.3.0331 · Cited by 2,614
Brain corticosteroid receptor balance in health and disease
de Kloet, E. R. (1998) · Endocrine Reviews · doi:10.1210/er.19.3.269 · Cited by 2,614
Mediators and Moderators of Treatment Effects in Randomized Clinical Trials
Kraemer, H. C., Wilson, G. T., Fairburn, C. G., & Agras, W. S. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.10.877 · Cited by 2,562 · cited 1×
“[14], treatment moderators are factors that “specify for whom and under which conditions the treatment works.”
BackgroundEpigenetic regulation in psychiatric disorders
Tsankova, N., Renthal, W., Kumar, A., & Nestler, E. J. (2007) · Nature reviews. Neuroscience · doi:10.1038/nrn2132 · Cited by 1,400 · cited 1×
“The discovery of those epigenetic modifications as a mechanism regulating longterm neurobiological adaptations and controlling over gene expression without altering the genetic code has added an additional level of complexity to depression research [60, 61].”
BackgroundMayberg, H. S., Brannan, S. K., Tekell, J. L., Silva, J. A., Mahurin, R. K., McGinnis, S., & Jerabek, P. A. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01036-2 · Cited by 1,115 · cited 1×
“An inverse pattern of serial changes in regional brain metabolism between responders and nonresponders to the treatment suggested that failure to induce these adaptive changes in brain metabolism may underlie treatment nonresponse [29].”
BackgroundBinder, E. B., Salyakina, D., Lichtner, P., Wochnik, G. M., Ising, M., Pütz, B., Papiol, S., Seaman, S., Lucae, S., Kohli, M. A., et al. (2004) · Nature Genetics · doi:10.1038/ng1479 · Cited by 977 · cited 1×
“Indeed, one of the most replicable findings in the pharmacogenetics of depression is that genetic variations in the 51 kDa immunophilin FKBP5 shape antidepressant treatment response [38–40].”
BackgroundKennedy, S. H., Evans, K. R., Krüger, S., Mayberg, H. S., Meyer, J. H., McCann, S., Arifuzzman, A. I., Houle, S., & Vaccarino, F. J. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.6.899 · Cited by 710 · cited 1×
“Different neuroimaging techniques, such as positron emission tomography (PET), magnetic resonance spectroscopy (MRS), and functional magnetic resonance imaging (fMRI) have all been used to study whether baseline, pretreatment characteristics or changes in brain functioning and metabolism correlate with symptom improve…”
MethodRaadsheer, F. C., Hoogendijk, W. J. G., Stam, F. C., Tilders, F. J. H., & Swaab, D. F. (2008) · Neuroendocrinology · doi:10.1159/000126778 · Cited by 667
The combined dexamethasone/CRH test: A refined laboratory test for psychiatric disorders
Heuser, I., Yassouridis, A., & Holsboer, F. (1994) · Journal of Psychiatric Research · doi:10.1016/0022-3956(94)90017-5 · Cited by 662
Holsboer, F. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(98)90056-5 · Cited by 654
Purba, J. S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830020055007 · Cited by 433
Kennedy, S. H., Konarski, J. Z., Segal, Z. V., Lau, M. A., Bieling, P. J., McIntyre, R. S., & Mayberg, H. S. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.5.778 · Cited by 420
Epigenetics of the depressed brain: role of histone acetylation and methylation
Sun, H., Kennedy, P. J., & Nestler, E. J. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.73 · Cited by 413 · cited 1×
“It has been suggested that the combination of certain environmental factors with genetic predispositions would result in an epigenetic and persistent dysregulation of central nervous system transcriptional programs, leading to phenotypic manifestation of the disease [62].”
BackgroundEndophenotype: a conceptual analysis
Kendler, K. S., & Neale, M. C. (2010) · Molecular Psychiatry · doi:10.1038/mp.2010.8 · Cited by 373
Personalized Medicine for Depression: Can We Match Patients With Treatments?
Simon, G. E., & Perlis, R. H. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09111680 · Cited by 365
Ising, M., Horstmann, S., Kloiber, S., Lucae, S., Binder, E. B., Kern, N., Künzel, H. E., Pfennig, A., Uhr, M., & Holsboer, F. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.07.039 · Cited by 341 · cited 1×
“Such a biomarker could support decision processes in antidepressant drug treatment even earlier than the full clinical improvement has developed and could also be assist in reducing attrition rates in the development of novel compounds [28].”
BackgroundPorcelli, S., Fabbri, C., & Serretti, A. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.10.003 · Cited by 331 · cited 1×
“One of the most replicated findings in the field of pharmacogenetics during the last years is the association between the short/long allele at the promoter of the serotonine transporter and the response to antidepressant treatment [37].”
BackgroundLekman, M., Laje, G., Charney, D., Rush, A. J., Wilson, A. F., Sorant, A. J. M., Lipsky, R., Wisniewski, S. R., Manji, H., McMahon, F. J., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.10.026 · Cited by 284
Epigenetic Mechanisms of Depression and Antidepressant Action
Vialou, V., Feng, J., Robison, A. J., & Nestler, E. J. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134540 · Cited by 277 · cited 1×
“The discovery of those epigenetic modifications as a mechanism regulating longterm neurobiological adaptations and controlling over gene expression without altering the genetic code has added an additional level of complexity to depression research [60, 61].”
BackgroundHow can drug discovery for psychiatric disorders be improved?
Agid, Y., Buzsáki, G., Diamond, D. M., Frackowiak, R., Giedd, J., Girault, J.-A., Grace, A., Lambert, J. J., Manji, H., Mayberg, H., et al. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2217 · Cited by 240
The Neuronal Transporter Gene SLC6A15 Confers Risk to Major Depression
Kohli, M. A., Lucae, S., Saemann, P. G., Schmidt, M. V., Demirkan, A., Hek, K., Czamara, D., Alexander, M., Salyakina, D., Ripke, S., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.04.005 · Cited by 228
Self-citationHow can we realize the promise of personalized antidepressant medicines?
Holsboer, F. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2453 · Cited by 177
Kemp, A. H., Gordon, E., Rush, A. J., & Williams, L. M. (2008) · CNS Spectrums · doi:10.1017/s1092852900017120 · Cited by 170 · cited 1×
“Among factors that have been shown to modulate antidepressant treatment response in major depression are disease severity, longer duration and frequency of the episodes, comorbid anxiety disorders, and an older age of onset [7].”
BackgroundDunlop, B. W., Binder, E. B., Cubells, J. F., Goodman, M. M., Kelley, M. E., Kinkead, B., Kutner, M., Nemeroff, C. B., Newport, D. J., Owens, M. J., et al. (2012) · Trials · doi:10.1186/1745-6215-13-106 · Cited by 136
Modulating limbic-cortical circuits in depression: Targets of antidepressant treatments
Mayberg, H. S. (2002) · Seminars in Clinical Neuropsychiatry · doi:10.1053/scnp.2002.35223 · Cited by 102
Shared genetics among major psychiatric disorders
Serretti, A., & Fabbri, C. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60223-8 · Cited by 77
Oved, K., Morag, A., Pasmanik-Chor, M., Oron-Karni, V., Shomron, N., Rehavi, M., Stingl, J. C., & Gurwitz, D. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.93 · Cited by 66 · cited 1×
“Evidence collected to date has already demonstrated that miRNA expression levels might be altered in patients suffering from depression [56] and could be considered an additional level of complexity for response biosignatures [57].”
Background
Cited by
Identification of MicroRNA-124-3p as a Putative Epigenetic Signature of Major Depressive Disorder
Roy, B., Dunbar, M., Shelton, R. C., & Dwivedi, Y. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.175 · Cited by 199
Blood biomarkers and treatment response in major depression
Mora, C., Zonca, V., Riva, M. A., & Cattaneo, A. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1470927 · Cited by 107
Brand, S., Moller, M., & Harvey, B. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150307004545 · Cited by 95
Wagner, S., Engel, A., Engelmann, J., Herzog, D., Dreimüller, N., Müller, M. B., Tadić, A., & Lieb, K. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.07.003 · Cited by 73
Mendez-David, I., Boursier, C., Domergue, V., Colle, R., Falissard, B., Corruble, E., Gardier, A. M., Guilloux, J.-P., & David, D. J. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00237 · Cited by 31
“Stimulated by the disappointing results of the genome wide association studies for antidepressant response, the potential of gene expression and proteomics as sources of predictive biosignatures have been explored (Labermaier et al., 2013).”
Background
Metadata
- Authors
- Labermaier, C., Masana, M., & Müller, M. B.
- Venue
- Disease Markers
- Publisher
- Wiley
- Published
- 2013
- Volume
- 35
- Issue
- 1
- Pages
- 23-31
- ISSN
- 0278-0240 (ISSN-L)
- 1875-8630
- OpenAlex
- W2066458367
- Cited by
- 75
- References
- 29
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.